A61L26/0028

Gel-forming agent comprising sulfa agent and chitosan agent and having powdered dosage form
10172975 · 2019-01-08 · ·

The present invention relates to a gel-forming agent comprising a sulfa agent and a chitosan agent and having a powdered dosage form. In addition, the present invention provides a kit comprising the gel-forming agent of the present invention and a method comprising a step for applying the gel-forming agent of the present invention. According to the present invention, a gel-forming agent is provided that demonstrates a therapeutic effect that is more remarkable than that of conventional sulfa agents and chitosan agents alone, and more particularly, a gel-forming agent for protecting an exudative affected area and a gel-forming agent for treating a wound. Namely, by the applying the combination of a sulfa agent and a chitosan agent in the form of a powder, the pH of the affected area is maintained in a range that demonstrates a therapeutic effect, and antibacterial action of the sulfa agent is demonstrated. In addition, the moist environment at the affected area is suitably maintained for suitable granulation. In addition, as a result of being a powder, the use of a suitable dissipating container enables the gel-forming agent to be dispersed by a person performing treatment without making direct contact with the affected area.

HEMOSTATIC COMPOSITION AND HEMOSTATIC METHOD USING HEMOSTATIC COMPOSITION
20180360904 · 2018-12-20 ·

[Problem] To provide a composition for hemostasis that can be applied uniformly to a bleeding site and exerts a high hemostatic effect. [Solution] Provided is a composition to be applied to the subject as a spray, wherein the composition is characterized in that the spray is for hemostasis, and the composition includes a self-assembling peptide, the self-assembling peptide gelling due to self-assembly when the composition is applied to the bleeding site of the subject, and the self-assembling peptide being included in the composition in a concentration having an improved hemostatic capacity in comparison to direct application.

ANTIMICROBIAL ARTICLES COMPRISING POLYURETHANE

The present invention provides an antimicrobial article comprising polyurethane, wherein said polyurethane is impregnated with a compound of Formula (I)


AA-AA-AA-XY (I)

The invention also provides polyurethane impregnated with a compound of Formula (I). The invention also provides compositions comprising at least one organic solvent, a thermoplastic polyurethane and a compound of Formula (I), and coatings produced using such compositions. The invention also provides methods of producing polyurethane impregnated with a compound of Formula (I), medical devices incorporating polyurethane impregnated with a compound of Formula (I), and medical uses of polyurethane impregnated with a compound of Formula (I).

METHOD OF STOPPING BLEEDING USING NANOFIBROUS PEPTIDE HYDROGELS AS HEMOSTASIS AGENT

The present disclosure relates generally to a method of stopping bleeding comprising applying a peptide-based hemostatic material to a bleeding wound, wherein the peptide-based hemostatic material comprises at least one self-assembling ultrashort peptide, and wherein an application of the peptide-based hemostatic material to the bleeding wound produces a coagulation time of less than 40 seconds. The present disclosure also provides a hand-held device for the application of the peptide-based hemostatic material.

DRY BIOCOMPATIBLE DISINTEGRATABLE FILMS FOR DELIVERING PARTICULATE EGG SHELL MEMBRANE TO A WOUND
20180325740 · 2018-11-15 ·

The invention provides a dry biocompatible film comprising at least one film forming material and particulate egg shell membrane (ESM), wherein said particulate ESM is distributed substantially uniformly in and/or on the film and wherein said film, or portion thereof, disintegrates upon contact with a wound or an exudate thereof. The invention further provides methods for preparing the films of the invention and the uses thereof in methods to promote the healing of wounds.

DISSOLVABLE HYDROGEL COMPOSITIONS FOR WOUND MANAGEMENT AND METHODS OF USE

The inventions provided herein relate to dissolvable hydrogel compositions and methods of uses, e.g., but not limited to, in wound management. Accordingly, methods for wound management involving the dissolvable hydrogel compositions are also provided herein. In some embodiments, the dissolvable hydrogel composition comprises an adhesive thioester hydrogel, which can facilitate adherence of the dissolvable hydrogen composition to a surface (e.g., a wound) and can be controllably dissolved later upon addition of a thiolate compound to release the dissolvable hydrogel composition from the surface (e.g., the wound).

Medical Graft Devices And Methods Of Making Thereof

Large-area medical graft devices comprise at least two sheets of extracellular matrix material (ECM). The sheets of ECM have overlapping regions that are compressed together during a non-drying process, and other overlapping regions that are not compressed together. The compressed overlapping regions have a more collapsed matrix structure, while the non-compressed overlapping regions having a more open matrix structure. The sheets of ECM can have a stacked orientation to create a desired thickness, or a staggered orientation to create a desired surface area, or combinations of both orientations.

COMPOSITIONS OF PARTIALLY DEACETYLATED CHITIN DERIVATIVES

The present invention relates to compositions comprising biologically active chitinous oligomers and their endotoxin purified and partially deacetylated chitin polymer precursors, and their use in pharmaceutical compositions, biomaterial compositions, medical devices, and processes to produce the said oligomers. More specifically the present invention relates to novel compositions and processes to produce such compositions. The compositions include therapeutic hetero polymer and hetero oligomer compositions comprising specific sequences of N-acetyl glucosamine and glucosamine, developed to optimize chemical and structural features which are important for the therapeutic activity of these compositions. In addition, the present invention provides methods to use degree of deacetylation of a partially deacetylated chitin polymer in order to modulate physical and biological parameters in a calcium phosphate composite for bone implant applications.

COMPOSITIONS OF PARTIALLY DEACETYLATED CHITIN DERIVATIVES

The present invention relates to compositions comprising biologically active chitinous oligomers and their endotoxin purified and partially deacetylated chitin polymer precursors, and their use in pharmaceutical compositions, biomaterial compositions, medical devices, and processes to produce the said oligomers. More specifically the present invention relates to novel compositions and processes to produce such compositions. The compositions include therapeutic hetero polymer and hetero oligomer compositions comprising specific sequences of N-acetyl glucosamine and glucosamine, developed to optimize chemical and structural features which are important for the therapeutic activity of these compositions. In addition, the present invention provides methods to use degree of deacetylation of a partially deacetylated chitin polymer in order to modulate physical and biological parameters in a calcium phosphate composite for bone implant applications.

Dissolvable hydrogel compositions for wound management and methods of use

The inventions provided herein relate to dissolvable hydrogel compositions and methods of uses, e.g., but not limited to, in wound management. Accordingly, methods for wound management involving the dissolvable hydrogel compositions are also provided herein. In some embodiments, the dissolvable hydrogel composition comprises an adhesive thioester hydrogel, which can facilitate adherence of the dissolvable hydrogen composition to a surface (e.g., a wound) and can be controllably dissolved later upon addition of a thiolate compound to release the dissolvable hydrogel composition from the surface (e.g., the wound).